Beyond Weight Loss: Wegovy Gains Landmark Approval to Treat Advanced Liver Disease (MASH)

In a major development for liver health, the FDA has granted accelerated approval for Wegovy (semaglutide) to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. The label update, effective August 2025, marks Wegovy as a pioneering treatment for this severe form of fatty liver disease, formerly known as NASH.

This new indication is based on clinical trial data showing Wegovy's ability to achieve resolution of MASH and improvement in liver fibrosis. The approval is granted under the FDA's accelerated pathway, meaning continued approval may depend on the results of ongoing confirmatory trials. This adds a critical new dimension to Wegovy's existing approvals for reducing major cardiovascular events and for chronic weight management in adults and adolescents with obesity or overweight.

The prescribing information continues to feature a boxed warning for the risk of thyroid C-cell tumors, a finding from rodent studies. Because of this potential risk, Wegovy is not recommended for patients with a personal or family history of medullary thyroid carcinoma (MTC). Other significant warnings include the risk of acute pancreatitis, acute gallbladder disease, hypoglycemia (especially when used with other diabetes medications), and suicidal ideation.

The most common side effects observed in clinical trials remain consistent across indications and include nausea, diarrhea, vomiting, constipation, abdominal pain, and headache. These are often most pronounced during the initial dose-escalation period.

This landmark approval offers a new therapeutic option for millions affected by MASH. To understand the full scope of this update, including dosage, administration, and complete safety data, it is essential to consult the official documentation. Click here to view the full prescribing information.